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summary
Pachymeningitis is a progressive disease resulting in a diffuse thickening of dura mater due to inflammation, 
tumor or autoimmune diseases, but most cases are idiopathic. Here, we report the case of a 60-year old man who 
had a progressive sensorineural hearing loss, visual disturbance and others cranial nerve involvement with an 
accompanying headache over several months. Brain magnetic resonance imaging showed diffusely thickened 
dura mater, highly enhanced after gadolinium administration, which was consistent with pachymeningitis. It 
was assumed to be related to autoimmune pathogenesis on the basis of elevated serum myeloperoxidase-anti-
neutrophil cytoplasmic antibody titers. After empirical steroid and cyclophosphamide therapy, the neurological 
problems were partially improved. Therefore, in the case of atypical sensorineural hearing loss accompanied by 
cranial nerve palsy or headache, pachymeningitis should be considered in the differential diagnosis. 
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n	 INTRODUCTION 
P
achymeningitis is a rare clinical en-
tity resulting in a diffuse thickening of 
dura mater. This disease has various etiolo-
gies including infection (such as syphilis 
or tuberculosis), neoplasm, or autoim-
mune disorders especially myeloperoxi-
dase-antineutrophil cytoplasmic antibody 
(MPO-ANCA) positive vasculitis. When 
an exhaustive evaluation fails to reveal 
a cause, idiopathic hypertrophic cranial 
pachymeningitis is considered. Pachymen-
ingitis can be complicated by cranial nerve 
involvement but it is rarely reported to lead 
to sensorineural hearing loss (1-4). Here, 
we present the case of a patient who had 
sensorineural hearing loss associated with 
other cranial nerve involvement revealing 
hypertrophic cranial pachymeningitis that 
was associated with positive MPO-ANCA.
n	 CASE REPORT
A 60-year old man, with no medical histo-
ry, was referred to our Department for pro-
gressive bilateral hearing impairment, vi-
sual disturbance and anosmia. He suffered 
from decreased visual acuity of both eyes, 
pain sensation with ocular movement. He 
also complained of recurrent nonspecific 
headache and dry mouth syndrome over 
three months without dry eye syndrome.
Neurologic examination showed right fa-
cial palsy (nerve VII) and hyperesthesia of 
the right hemiface (nerve V). The gag re-
flex was missing. 
An audiologic test revealed bilateral, severe 
mixed hearing loss with a mean threshold 
of 75 dB on the right ear and profound sen-
sorineural hearing loss with a mean thresh-
old of 90 dB on the left one in the pure 
tone audiogram. Ophthalmologic exami-
nation showed both peripapillary edemas 
that were consistent with optic neuropathy. 
The Schirmer test was negative. Other neu-
rologic examinations yielded exaggerated 
deep tendon reflexes especially patellar and 
Achilles reflex with negative Babinski. The 
rest of the clinical examination was normal. 
Laboratory examination revealed that the 
C-reactive protein (CRP) concentration 
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was markedly elevated at 110 mg/L (0-
3.0 mg/L). The erythrocyte sedimentation 
rate (ESR) was at 120 mm H1. A complete 
blood picture showed white blood cell: 
15,640/μL, platelet: 273,000/μL, eosino-
philic granulocyte: 30/μL and hemoglobin: 
15.6 g/dL. Protein electrophoresis with im-
munoglobulin, renal and liver function tests 
proved normal. There was no proteinuria.
Cerebrospinal fluid (CSF) examination 
showed elevated protein level 1.66 g/L (N: 
0.15-0.40), 4.24 mmol/L glucose (N: 1.5-
4) and 6 white cells per cubic millimeter. 
The virologic, parasitologic and bacterio-
logic analyses were negative. Carcinoma-
tous cells were not detected in the CSF 
sample. Brain magnetic resonance imag-
ing (MRI) demonstrated diffusely thick-
ened dura mater that was hypertrophic in 
some sites on the left cerebral hemisphere. 
The T2-weighted images showed diffuse 
thickening of the dura mater. The menin-
ges were highly enhanced after gadolinium 
administration, which was consistent with 
pachymeningitis (Fig. 1).
All known causes of pachymeningitis were 
explored. Investigations for tuberculosis, 
brucellosis, syphilis, Lyme disease, Ep-
stein Barr virus, cytomegalovirus, herpes 
simplex virus, human immunodeficiency 
virus were negative. The titer of angioten-
sin-converting enzyme (ACE) was normal 
at 25 U (Normal value: 19.8-70.2 U).
Antineutrophil cytoplasmic antibody were 
screened by indirect immunofluorescence 
technique and then tested by enzyme‐
linked immunosorbent assay (ELISA) for 
circulating MPO and PR3 antibodies.
The titer of ANCA for myeloperoxidase 
was positive. Other autoimmune antibod-
ies, such as, rheumatoid factor, comple-
ment activation, c-ANCA, antinuclear an-
tibody (DNA, SSA, and SSB), anticardio-
lipin antibody were negative.
The focus score was inferior to 1 on the 
biopsy of a salivary gland according to 
the classification by Chisholm and Mason 
1968; and there was absence of noncase-
ating granulomas, histiocytes, Langerhans 
and foreign body giant cells. A chest X-ray 
and chest computed tomography showed 
no evidence of neoplasm, sarcoidosis or re-
Figure 1 - Brain mag-
netic resonance im-
aging (MrI): axial (a), 
coronal (B) and sag-
ittal (c) t1-weighted 
contrast-enhanced 
MrI images show 
markedly thickened 
and enhanced dura 
extending from the 
vertex to the tento-
rium (arrow).
a
B
C
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cent tuberculosis. The cause of pachymen-
ingitis, including sarcoidosis, tuberculosis 
meningitis, rheumatoid arthritis, syphilis, 
and occult malignancy, was sought and was 
excluded with negative laboratory results 
and absence of related clinical symptoms.
Though histological confirmation was not 
obtained, the patient was highly suspected 
to have cranial pachymeningitis related to 
autoimmune pathogenesis on the basis of 
elevated serum MPO-ANCA. The patient 
was started on oral prednisone at a dose 
of 60 mg per day during two months with 
a progressive tapering, associated with 
monthly intravenous pulses of cyclophos-
phamide (1 g per month).
During the administration of steroids and 
cyclophosphamide, his headache gradu-
ally subsided. Over a 6-month treatment 
period, visual loss and hearing impairment 
gradually improved.
On repeat audiologic testing, the pure tone 
threshold was partially improved in the 
right ear (40 dB) more than the left one 
(80 dB) when compared with the initial 
pure tone audiogram. The visual problems 
showed a favorable response to treatment 
and papilledema disappeared. The ESR, 
the CRP and the blood regular test returned 
normal. The MPO-ANCA titer gradually 
decreased to be within the normal range. 
n	 DISCUSSION
Our patient presented with multiple cranial 
nerve palsy (I, II, V, VII and VIII) reveal-
ing hypertrophic pachymeningitis associ-
ated with positive MPO-ANCA, which 
was confirmed by neuroimaging and which 
improved with the association of cortico-
steroids and cyclophosphamid.
Pachymeningitis is a progressive rare in-
flammatory disease resulting in a localized 
or diffuse thickening of the dura mater, 
leptomeninges, and tentorium. Since the 
introduction of MRI, hypertrophic pachy-
meningitis has been increasingly reported 
in recent literature (1-8).
The clinical presentation can be hetero-
geneous (7, 9): headache, cranial nerve 
palsy, cerebellar ataxia, internal carotid ar-
tery occlusion, venous sinus occlusion and 
obstructive hydrocephalus. Other clinical 
presentations include diabetic insipidus 
with hypophysitis, and sinus thrombosis 
(10). In pachymeningitis, cranial nerve in-
volvement is of concern due to high intra-
cranial pressure resulting from thickened 
dura mater; or it may be directly caused by 
small-vessel vasculitis or indirectly by the 
inflammatory process of the surrounding 
soft tissue or of the meninges (11). Cranial 
nerve VIII is the most frequently involved 
cranial nerve (2-4, 12) and it represents a 
form of sensorineural hearing loss that is 
sometimes reversible. The next most fre-
quently involved are cranial nerves V, VII, 
IX, X, and XII, with equal frequency (13). 
In most cases of pachymeningitis, optic 
nerve involvement is reported along with 
headache (14). Visual deterioration or 
blindness has also been described in a few 
reports (10). 
Our patient had rapidly progressive mixed 
hearing loss on the right ear and sensori-
neural hearing loss on the left ear due to 
pachymeningitis. After steroid treatment 
associated with cyclophosphamide, the 
pure tone threshold improved by 35 dB in 
the right and 10 dB in the left ear.
Therefore, in cases of atypical sensori-
neural hearing loss, such as hearing loss 
that progresses relatively rapidly, or when 
neurologic signs coexist, the possibility of 
autoimmune pathogenesis should be taken 
into consideration. 
The etiology of pachymeningitis is diverse 
and includes infectious diseases such as 
tuberculosis, syphilis, tumors and auto-
immune disorders especially Wegener’s 
granulomatosis (15), microscopic poly-
angeitis (8), relapsing polychondritis (16), 
rheumatoid arthritis, Sjogren’s syndrome 
(17), sarcoidosis but mostly it is idiopathic. 
Recently, more research on the relationship 
between pachymeningitis and autoimmune 
diseases has been carried out. Moreover, 
there have been several reports about pachy-
meningitis with autoimmune antibody. In 
particular, the relationship between AN-
CA-positive pachymeningitis and vasculi-
tis has been discussed (5, 6, 18, 19). In our 
case, the initial clinical presentation and 
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subsequent remission under immunosup-
pressive therapy were suggestive of a vas-
culitis with nervous system involvement, 
though vasculitis was not proven histologi-
cally in this patient. Also, it was reported 
that the titer of MPO-ANCA decreases as 
the disease gradually improves through im-
munosuppressive treatment (12). Hence, it 
is suggested that an MPO-ANCA titer can 
be used as a monitoring marker of the dis-
ease’s activity in such patients (12, 20). 
The diagnosis of neurosarcoidosis can be 
difficult when neurological involvement is 
the first or only manifestation of the dis-
ease. In our patient, ACE level was normal, 
serum calcium, chest X-rays and the biop-
sy were normal and ruled out sarcoidosis.
To diagnose pachymeningitis, MRI with 
gadolinium enhancement is the most sen-
sitive diagnostic imaging modality, and 
shows the relationship between the inflam-
matory degree of the lesion and the clinical 
outcome, as well as the prognosis (1, 12, 
21). Generally, in MRI, T1-weighted im-
ages show iso- or hypo-intense thickened 
dura mater, and T2-weighted images show 
hypointense dura mater of fibrous reacting 
tissue surrounded by a thin hyperintense 
border attributed to the acute inflammatory 
process. Distinctively, meninges are highly 
enhanced after a contrast injection (12, 21).
Although almost cases of hypertrophic 
pachymeningitis appear responsive to cor-
ticosteroid therapy, some patients require 
combined therapy with corticosteroid and 
other immunosuppressive drugs (cyclo-
phosphamide, azathioprine, methotrexate) 
because of the severity of symptoms as 
seen in the present case; or in case of pro-
gressive disease despite treatment. 
Among 33 patients with idiopathic cranial 
hypertrophic meningitis, 62, 6% experi-
enced full remission without steroid de-
pendence, 15% experienced steroid depen-
dent partial or complete remission, 15% 
experienced a progressive course inspite of 
steroid therapy, and 32% died regardless of 
treatment (9).
In our patient, we chose combination of 
corticosteroid and intravenous pulses of 
cyclophosphamid (1 g per month). We 
noted a spectacular improvement within 6 
months. There is no consensus about the 
duration of this therapy. After minimum 12 
months we will try to stop the cyclophos-
phamid after brain MRI control.
n	 CONCLUSIONS
In the case of hearing impairment accompa-
nying other cranial neuropathy, pachymen-
ingitis should be taken into consideration, 
and brain MRI with gadolinium enhance-
ment is the best method of detecting it.
Though vasculitis was not proven histolog-
ically in our patient, we believe that MPO-
ANCA-related autoimmunity provoked 
the patient’s disease as already reported 
in similar cases. So, a cautious evaluation 
including an ANCA work-up should be 
performed. We conclude that early recog-
nition of an autoimmune etiology, even in 
the absence of previous pulmonary or renal 
involvement, is required to ensure proper 
treatment and prevent definitive neurologi-
cal impairment.
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